Search hospitals
>
Wisconsin
>
Milwaukee
Children's Hospital of Wisconsin
Claim this profile
Milwaukee, Wisconsin 53226
Global Leader in Cancer
Global Leader in Brain Tumor
Conducts research for Solid Tumors
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Neuroblastoma
414 reported clinical trials
26 medical researchers
Summary
Children's Hospital of Wisconsin is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Brain Tumor, Solid Tumors, Acute Lymphoblastic Leukemia, Neuroblastoma and other specialties. Children's Hospital of Wisconsin is involved with conducting 414 clinical trials across 691 conditions. There are 26 research doctors associated with this hospital, such as Paul D. Harker-Murray, Meghen B. Browning, Michael Burke, MD, and Julie-An Talano.
Area of expertise
Cancer
Children's Hospital of Wisconsin has run 67 trials for Cancer. Some of their research focus areas include:
Brain Tumor
Children's Hospital of Wisconsin has run 42 trials for Brain Tumor. Some of their research focus areas include:
Top PIs
Paul D. Harker-Murray
Children's Hospital of Wisconsin
8 years of reported clinical research
Meghen B. Browning
Children's Hospital of Wisconsin
19 years of reported clinical research
Michael Burke, MD
Children's Hospital of Wisconsin
2 years of reported clinical research
Julie-An Talano
Medical College of Wisconsin
6 years of reported clinical research
Clinical Trials running at Children's Hospital of Wisconsin
Leukemia
Acute Lymphoblastic Leukemia
Burkitt Lymphoma
Cancer
Retinoblastoma
Testicular cancer
Biphenotypic Leukemia
Neuroblastoma
Lymphoma
Acute Myelogenous Leukemia
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting
2 awards
Phase 3
Blinatumomab + Dasatinib/Imatinib
for Acute Lymphoblastic Leukemia
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with Ph+ or Ph-like ABL-class B-ALL than dasatinib or imatinib with chemotherapy.
Recruiting
2 awards
Phase 3
5 criteria
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Children's Hospital of Wisconsin?
Children's Hospital of Wisconsin is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Brain Tumor, Solid Tumors, Acute Lymphoblastic Leukemia, Neuroblastoma and other specialties. Children's Hospital of Wisconsin is involved with conducting 414 clinical trials across 691 conditions. There are 26 research doctors associated with this hospital, such as Paul D. Harker-Murray, Meghen B. Browning, Michael Burke, MD, and Julie-An Talano.
Where is Children's Hospital of Wisconsin located?
**Children's Hospital of Wisconsin** - **Address:** 8915 W Connell Ct, Milwaukee, WI 53226 - **Directions:** From I-94 W, take exit 309B for 84th St towards Wauwatosa. Turn right onto W North Ave, then left onto N 84th St. After 0.5 miles, turn right onto W Connell Ave. The hospital is on your left.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Children's Hospital of Wisconsin, contact them at (414) 266-6262 or via email at FinancialAssistance@childrenswi.org. For insurance inquiries, reach out to their main switchboard at (414) 266-2000 or toll-free at (877) 266-8989. Their mailing address is 8915 W. Connell Ct. P.O. Box 1997, Milwaukee, WI 53226.
What insurance does Children's Hospital of Wisconsin accept?
Children's Hospital of Wisconsin accepts a wide range of insurance plans, ensuring access to high-quality healthcare for its patients. Among these, Chorus Community Health Plans (CCHP), an affiliate of Children's Wisconsin, offers BadgerCare Plus in 28 counties and Individual and Family Plans across 15 counties in eastern Wisconsin. Additionally, the hospital is in-network with numerous other insurers, including but not limited to Aetna, Anthem Wisconsin, Cigna Health Plan, Humana, Medicaid Wisconsin, Medicare, and UnitedHealthcare.
What awards or recognition has Children's Hospital of Wisconsin received?
Children's Hospital of Wisconsin in Milwaukee is renowned for its outstanding patient care, employer practices, and community partnerships. It has also been recognized for its significant contributions to pediatric science through its nursing research and evidence-based practice department. This department has developed a support network for pediatric nurse scientists, fostering nurse-led, collaborative research across various disciplines and sites.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.